Provided by Tiger Fintech (Singapore) Pte. Ltd.

Scilex Holding Company

6.02
-0.1000-1.63%
Post-market: 5.74-0.2763-4.59%18:58 EDT
Volume:108.77K
Turnover:655.64K
Market Cap:41.54M
PE:-9.88
High:6.32
Open:6.06
Low:5.80
Close:6.12
Loading ...

Company Profile

Company Name:
Scilex Holding Company
Exchange:
NASDAQ
Establishment Date:
- -
Employees:
115
Office Location:
960 San Antonio Road,Palo Alto,California,United States
Zip Code:
94303
Fax:
- -
Introduction:
Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.